GBA1 and respiratory system disorder: The first drug is ambroxol (trans-4-(2-amino-3,5-dibromobenzylamino)-cyclohexanol hydrochloride), a secretolytic agent commonly used in the treatment of respiratory diseases associated with viscid or excessive mucus [34], which was found able to enhance the activity of beta-glucocerebrosidase (GCase) [35,36] and to improve the progression of neurological symptoms in a clinical trial on Gaucher patients [37].